Lv41
448 积分 2025-09-28 加入
Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial
16天前
已关闭
Abstract CT003: Initial results of a phase 1 study of AMG 355, a novel anti-CCR8 antibody as a single agent and in combination with pembrolizumab in patients with solid tumors
16天前
已完结
Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies
16天前
已关闭
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies
16天前
已完结
Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors
16天前
已关闭
Claudin 18.2–Targeted CAR T-Cell Therapy (CT041) in Patients With Advanced Gastric/Gastroesophageal Junction Cancer: Final Results of a Phase I Trial
16天前
已完结
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
17天前
已完结
皖公网安备34019202002308
